Published in Cell Mol Neurobiol on September 10, 2008
Brain Tumor Stem-Like Cells Identified by Neural Stem Cell Marker CD15. Transl Oncol (2009) 1.06
CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia. Neuro Oncol (2013) 0.94
Gliomagenesis and the use of neural stem cells in brain tumor treatment. Anticancer Agents Med Chem (2010) 0.86
Recovery of CNS pathway innervating the sciatic nerve following transplantation of human neural stem cells in rat spinal cord injury. Cell Mol Neurobiol (2011) 0.81
Maintenance of critical properties of brain tumor stem-like cells after cryopreservation. Cell Mol Neurobiol (2010) 0.81
The potential of the brain: plasticity implications for de-differentiation of mature astrocytes. Cell Mol Neurobiol (2009) 0.79
LGR5 is a proneural factor and is regulated by OLIG2 in glioma stem-like cells. Cell Mol Neurobiol (2013) 0.77
Malignant behaviorial characteristics of CD133(+/-) glioblastoma cells from a Northern Chinese population. Exp Ther Med (2012) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Identification of human brain tumour initiating cells. Nature (2004) 38.87
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Identification of a cancer stem cell in human brain tumors. Cancer Res (2003) 24.02
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science (1992) 19.30
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res (2004) 14.73
Mechanisms and functional implications of adult neurogenesis. Cell (2008) 14.50
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature (2003) 12.06
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature (2006) 11.86
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56
Tumor growth need not be driven by rare cancer stem cells. Science (2007) 10.34
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Primary bioassay of human tumor stem cells. Science (1977) 9.69
Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 9.27
Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science (2004) 9.10
Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci (2005) 8.96
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Stem cells and their niches. Science (2006) 7.86
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (2006) 7.69
Stem cells and cancer; the polycomb connection. Cell (2004) 7.43
Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science (2001) 6.84
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A (2004) 6.84
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res (2007) 6.21
Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res (2005) 5.87
Brain tumour stem cells. Nat Rev Cancer (2006) 5.84
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia (2002) 5.81
Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev (2005) 5.78
Neural stem cells and the origin of gliomas. N Engl J Med (2005) 5.43
Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A (2004) 5.32
Radial glia cells are candidate stem cells of ependymoma. Cancer Cell (2005) 5.21
HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol (2006) 5.17
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90
Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature (2004) 4.82
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 4.29
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science (1997) 4.26
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Differential Notch signalling distinguishes neural stem cells from intermediate progenitors. Nature (2007) 4.02
The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood (2002) 4.02
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci (2003) 3.98
Cancer stem cells: lessons from leukemia. Trends Cell Biol (2005) 3.90
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006) 3.81
Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron (2003) 3.76
Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A (2000) 3.69
Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat Neurosci (2005) 3.67
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
CD133: molecule of the moment. J Pathol (2008) 3.58
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (2007) 3.47
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A (2007) 3.23
Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res (2008) 3.22
The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development (2001) 3.14
Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell (2007) 3.14
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer (2005) 3.01
Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development (2005) 2.97
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst (2001) 2.90
Notch signaling in stem cell systems. Stem Cells (2006) 2.82
A side order of stem cells: the SP phenotype. Stem Cells (2006) 2.73
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008) 2.61
Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood (2002) 2.44
Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg (2007) 2.43
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle (2006) 2.37
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35
PTENless means more. Dev Biol (2004) 2.31
ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev (2007) 2.31
A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis. Nat Neurosci (2005) 2.30
Identifying cancer stem cells in solid tumors: case not proven. Cancer Res (2006) 2.28
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol (2006) 2.11
An overview of the Notch signalling pathway. Semin Cell Dev Biol (2003) 1.93
Sequential actions of BMP receptors control neural precursor cell production and fate. Genes Dev (2001) 1.84
Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia (2006) 1.82
Adult neurogenesis requires Smad4-mediated bone morphogenic protein signaling in stem cells. J Neurosci (2008) 1.81
Notch signaling enhances nestin expression in gliomas. Neoplasia (2006) 1.73
Wnt signaling: multiple functions in neural development. Cell Mol Life Sci (2005) 1.64
Pten signaling in gliomas. Neuro Oncol (2002) 1.62
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res (2007) 1.60
Cancer stem cells persist in many cancer cell lines. Cell Cycle (2004) 1.58
CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res (2007) 1.58
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem (2008) 1.52
The hedgehog pathway and neurological disorders. Annu Rev Neurosci (2006) 1.51
Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol (2007) 1.50
Sub-diffraction-limited optical imaging with a silver superlens. Science (2005) 7.67
Plasmon lasers at deep subwavelength scale. Nature (2009) 4.93
Three-dimensional optical metamaterial with a negative refractive index. Nature (2008) 4.87
A graphene-based broadband optical modulator. Nature (2011) 4.21
A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med (2009) 4.20
An optical cloak made of dielectrics. Nat Mater (2009) 4.16
Far-field optical hyperlens magnifying sub-diffraction-limited objects. Science (2007) 4.14
Optical negative refraction in bulk metamaterials of nanowires. Science (2008) 3.28
Ultrasonic metamaterials with negative modulus. Nat Mater (2006) 2.91
Plasmon-induced transparency in metamaterials. Phys Rev Lett (2008) 2.88
Experimental demonstration of an acoustic magnifying hyperlens. Nat Mater (2009) 2.82
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Photonic spin Hall effect at metasurfaces. Science (2013) 2.04
Phase mismatch-free nonlinear propagation in optical zero-index materials. Science (2013) 1.90
Edge nonlinear optics on a MoS₂ atomic monolayer. Science (2014) 1.83
Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One (2013) 1.81
Room-temperature sub-diffraction-limited plasmon laser by total internal reflection. Nat Mater (2010) 1.73
Switching terahertz waves with gate-controlled active graphene metamaterials. Nat Mater (2012) 1.72
Probing the electromagnetic field of a 15-nanometre hotspot by single molecule imaging. Nature (2011) 1.72
Space-time crystals of trapped ions. Phys Rev Lett (2012) 1.71
Photoinduced handedness switching in terahertz chiral metamolecules. Nat Commun (2012) 1.69
Flying plasmonic lens in the near field for high-speed nanolithography. Nat Nanotechnol (2008) 1.65
Spherical hyperlens for two-dimensional sub-diffractional imaging at visible frequencies. Nat Commun (2010) 1.61
Transformational plasmon optics. Nano Lett (2010) 1.61
Plasmonic Luneburg and Eaton lenses. Nat Nanotechnol (2011) 1.59
DISCO: distance and spectrum correlation optimization alignment for two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Anal Chem (2010) 1.58
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood (2009) 1.58
Double-layer graphene optical modulator. Nano Lett (2012) 1.56
A carpet cloak for visible light. Nano Lett (2011) 1.55
Negative refractive index in chiral metamaterials. Phys Rev Lett (2009) 1.55
High-Q surface-plasmon-polariton whispering-gallery microcavity. Nature (2009) 1.52
All optical interface for parallel, remote, and spatiotemporal control of neuronal activity. Nano Lett (2007) 1.49
Wavelet- and Fourier-transform-based spectrum similarity approaches to compound identification in gas chromatography/mass spectrometry. Anal Chem (2011) 1.49
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell (2007) 1.45
Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry peak sorting algorithm. J Chromatogr A (2007) 1.42
MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. Biochem Biophys Res Commun (2012) 1.40
Far-field optical superlens. Nano Lett (2007) 1.39
Common aspects of human and primate seronegative arthritis. J Rheumatol (2004) 1.39
Focusing surface plasmons with a plasmonic lens. Nano Lett (2005) 1.39
Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol (2012) 1.37
Performance evaluation of existing de novo sequencing algorithms. J Proteome Res (2006) 1.36
Metamaterials: a new frontier of science and technology. Chem Soc Rev (2011) 1.34
Compound identification using partial and semipartial correlations for gas chromatography-mass spectrometry data. Anal Chem (2012) 1.34
Light-driven nanoscale plasmonic motors. Nat Nanotechnol (2010) 1.33
Observation of stimulated emission of surface plasmon polaritons. Nano Lett (2008) 1.32
Maskless plasmonic lithography at 22 nm resolution. Sci Rep (2011) 1.31
Cloaking of matter waves. Phys Rev Lett (2008) 1.28
A method of calculating the second dimension retention index in comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry. J Chromatogr A (2011) 1.28
A method of finding optimal weight factors for compound identification in gas chromatography-mass spectrometry. Bioinformatics (2012) 1.27
Axon initiation and growth cone turning on bound protein gradients. J Neurosci (2009) 1.27
Strong coupling of surface plasmon polaritons in monolayer graphene sheet arrays. Phys Rev Lett (2012) 1.27
Self-amplifying autocrine actions of BDNF in axon development. Proc Natl Acad Sci U S A (2011) 1.25
MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett (2012) 1.22
An optimal peak alignment for comprehensive two-dimensional gas chromatography mass spectrometry using mixture similarity measure. Bioinformatics (2011) 1.22
Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res (2005) 1.21
Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China. Trop Med Int Health (2007) 1.21
Roles of GRP78 in physiology and cancer. J Cell Biochem (2010) 1.20
Subwavelength discrete solitons in nonlinear metamaterials. Phys Rev Lett (2007) 1.20
MetSign: a computational platform for high-resolution mass spectrometry-based metabolomics. Anal Chem (2011) 1.19
Measuring financial protection for health in families with chronic conditions in Rural China. BMC Public Health (2012) 1.18
Neural network prediction of peptide separation in strong anion exchange chromatography. Bioinformatics (2006) 1.17
Passivation mechanism of thermal atomic layer-deposited Al2O3 films on silicon at different annealing temperatures. Nanoscale Res Lett (2013) 1.15
The effect of nonsense codons on splicing: a genomic analysis. RNA (2003) 1.15
Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS (2004) 1.13
Development of optical hyperlens for imaging below the diffraction limit. Opt Express (2007) 1.13
Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer (2005) 1.12
Nonparaxial Mathieu and Weber accelerating beams. Phys Rev Lett (2012) 1.11
iMatch: a retention index tool for analysis of gas chromatography-mass spectrometry data. J Chromatogr A (2011) 1.11
A hierarchical statistical model to assess the confidence of peptides and proteins inferred from tandem mass spectrometry. Bioinformatics (2007) 1.11
How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev (2009) 1.10
Environmental epigenetics and its implication on disease risk and health outcomes. ILAR J (2012) 1.10
Health-related quality of life in patients with high-grade glioma. Neuro Oncol (2008) 1.10
Heterojunction silicon microwire solar cells. Nano Lett (2012) 1.10
New enlightenment of French Paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther (2007) 1.09
Expression of androgen receptor is negatively regulated by p53. Neoplasia (2007) 1.08
Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. OMICS (2004) 1.08
Multiplexed and electrically modulated plasmon laser circuit. Nano Lett (2012) 1.08
Plasmonic Airy beams with dynamically controlled trajectories. Opt Lett (2011) 1.07
Brain Tumor Stem-Like Cells Identified by Neural Stem Cell Marker CD15. Transl Oncol (2009) 1.06
Metabolomic analysis of the effects of polychlorinated biphenyls in nonalcoholic fatty liver disease. J Proteome Res (2012) 1.06
MetPP: a computational platform for comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Bioinformatics (2013) 1.06
Exacerbation of diabetes-induced testicular apoptosis by zinc deficiency is most likely associated with oxidative stress, p38 MAPK activation, and p53 activation in mice. Toxicol Lett (2010) 1.05
Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc Surg (2008) 1.05
Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci (2006) 1.04
Recent advances in transformation optics. Nanoscale (2012) 1.04
Experimental certification of random numbers via quantum contextuality. Sci Rep (2013) 1.04
Association of elevated GRP78 expression with increased astrocytoma malignancy via Akt and ERK pathways. Brain Res (2010) 1.03
HTreeQA: Using Semi-Perfect Phylogeny Trees in Quantitative Trait Loci Study on Genotype Data. G3 (Bethesda) (2012) 1.03
An optical "Janus" device for integrated photonics. Adv Mater (2010) 1.03
Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol (2007) 1.02
Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol (2010) 1.01
Optical forces in hybrid plasmonic waveguides. Nano Lett (2011) 1.01
Symmetry breaking and optical negative index of closed nanorings. Nat Commun (2012) 1.01
Ultrafast modulation of optical metamaterials. Opt Express (2009) 1.01
Data preprocessing method for liquid chromatography-mass spectrometry based metabolomics. Anal Chem (2012) 1.01
Comparative analysis of mass spectral matching-based compound identification in gas chromatography-mass spectrometry. J Chromatogr A (2013) 1.00
Surface plasmon interference nanolithography. Nano Lett (2005) 1.00